Takeda’s dengue vaccine candidate offers protection against dengue fever in clinical trial

TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union

Sanofi Dupixent gets USFDA nod for atopic dermatitis

Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood

Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod

Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis

Merck and Ridgeback announce new data for investigational molnupiravir

Based on a post hoc analysis, fewer required respiratory interventions

Halozyme announces commercial launch of testosterone undecanoate 'TLANDO'

TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.

Phygital model of med-tech seems to be quite Promising: opines Expert

To address the preventive & primary healthcare delivery gaps in India

GSK to acquire clinical-stage biopharmaceutical company Affinivax for US$ 3.3 billion

GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones

FDA approves Roche’s Evrysdi for use in babies under two months with SMA

Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date

Mezzion Pharma receives clear FDA path forward for the approval of Udenafil for single ventricle heart disease

MVA-BN respiratory syncytial virus vaccine could get first-to-market opportunity in China, says GlobalData

RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised